[2]Papa F, Grinda T, Rassy E, et al. Long road towards effective HER3 targeting in breast cancer. Cancer Treat Rev. Published online June 13, 2024. doi:10.1016/j.ctrv.2024.102786 [3]Amin DN, Campbell MR, Mo...
PURPOSE: Human epidermal growth factor receptor 3 (HER3) is broadly expressed in breast cancer; high expression is associated with an adverse prognosis. Patritumab deruxtecan (HER3-DXd) is an investigational HER3-targeted antibody-drug conjugate that is bein...
Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol 2007;39:851-6Michalis V. Karamouzis, Filitsa A. Badra, Athanasios G. Papavassiliou. Breast cancer: The upgraded role of HER‐3 and HER‐4. The International Journal...
4、HER3相关产品与服务助力HER3生物疗法开发 HER3蛋白&抗体&细胞株&CDX切片 HER3先导抗体分子研究进展 参考文献：[1]Maennling AE, Tur MK, Niebert M, Klockenbring T, Zeppernick F, Gattenlohner S, et al. Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Poten...
New era for emerging therapeutic targeting human epidermal growth factor receptor 3 (HER 3) in advanced nonsmall cell lung cancer and metastatic breast cancer.Yasar Ahmed|Thamir Mahgoub|Maha Al Sindi|José J. Berenguer‐Pina MedComm – Oncology. 2022;e19.doi:10.1002/mog2.19...
随着临床试验的深入和新药的不断开发,我们期待HER3靶向治疗能为乳腺癌患者带来更有效的治疗选择。 参考文献 [1] Papa F, Grinda T, Rassy E, Cheickh-Hussin R, Ribeiro J, Antonuzzo L, Pistilli B. Long road towards effective HER3 targeting in breast cancer. Cancer Treat Rev. 2024 Jun 13;129:...
Front Mol Biosci. 2022;9: 847835. 2. Implementing antibody-drugconjugates (ADCs) in HER2-positive breast cancer: state of the art and futuredirections. Breast Cancer Res. 2021; 23: 84. 更多生物制药知识尽在微信公众号"小药说药", 欢迎大家关注阅览!
参考文献:New era for emerging therapeutic targeting humanepidermal growth factor receptor 3 (HER 3) in advanced nonsmall cell lung cancer and metastatic breast cancer.Yasar Ahmed|Thamir Mahgoub|Maha Al Sindi|José J. Berenguer‐PinaMedComm – Oncology. 2022;e19.doi:10.1002/mog2.19 ...
[5]Krop IE,et al.Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).ASCO 2022.abstr 1002. 专家简介 王树森教授 ...
Jain博士还测试了靶向HER3对其他几种肿瘤的治疗效果,发现该治疗策略可能会使更多的患者受益。她希望,未来HER2+脑转移型或PIK3CA突变型乳腺癌的临床试验和治疗策略可以引入靶向HER3的药物/手段。 原文标题:The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activati...